Israel Lowy

机构：Regeneron (United States), Progenics Pharmaceuticals (United States) · ORCID：0000-0002-5421-2485

发表论文 339 篇 · 总被引 24281 次 · h-index 59

代表论文

• Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma (2025 · New England Journal of Medicine · 被引 82)
• Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1 (2025 · Journal of Thoracic Oncology · 被引 29)
• Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial (2025 · European Journal of Cancer · 被引 27)
• Abstract CT013: Phase I trial evaluating BNT116, a TAA-encoding mRNA vaccine, in combination with cemiplimab in frail patients with advanced non-small cell lung cancer (NSCLC) (2025 · Cancer Research · 被引 12)
• Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial (2025 · Gynecologic Oncology · 被引 10)
• A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC). (2025 · Journal of Clinical Oncology · 被引 4)